Boston Scien Cp Stock Price, News & Analysis

Boston Scientific (NYSE: BSX) has completed its acquisition of Silk Road Medical, Inc. (Nasdaq: SILK) for $27.50 per share, representing an enterprise value of approximately $1.18 billion. This acquisition strengthens Boston Scientific's vascular technology solutions by integrating the innovative transcarotid artery revascularization (TCAR) platform for stroke prevention and carotid artery disease treatment.

The deal is expected to have a minimal impact on Boston Scientific's adjusted earnings per share in 2024 and 2025, becoming accretive thereafter. The impact on GAAP earnings may be less favorable due to amortization expenses and acquisition-related charges. This strategic move aims to expand the availability of TCAR to more physicians and patients through Boston Scientific's extensive commercial network.

Boston Scientific (NYSE: BSX) has received FDA approval to expand the indication for its INGEVITY™+ Pacing Leads to include conduction system pacing (CSP) and sensing of the left bundle branch area (LBBA). This expansion allows for an alternative to traditional right ventricular pacing in treating symptomatic bradycardia. The LBBA pacing approach may promote greater ventricular synchrony and reduce long-term heart failure risk.

The approval was supported by data from the INSIGHT-LBBA study, involving approximately 400 patients. The INGEVITY+ Pacing Lead, which received initial FDA approval in 2019, features a stylet-driven design for precise positioning and continuous pacing and impedance monitoring capabilities.

Boston Scientific (NYSE: BSX) has obtained CE mark for its ACURATE Prime™ Aortic Valve System, a new transcatheter aortic valve replacement (TAVR) technology. This system expands treatment options for patients with larger anatomy and is designed for low, intermediate, and high-risk patients with severe aortic stenosis. Key features include:

- An enhanced frame for stable fit
- Redesigned deployment mechanism for accurate positioning
- Expanded treatment range (aortic annulus diameters 20.5-29 mm)
- Low pacemaker and paravalvular leak rates
- Strong hemodynamic performance
- Unrestricted coronary access for future procedures

The ACURATE Prime system will be launched in Europe in the coming weeks, building on the success of the ACURATE platform, which has been implanted in nearly 80,000 patients globally.

Boston Scientific (NYSE: BSX) has announced its participation in Wells Fargo's 2024 Healthcare Conference on September 4, 2024. The company's chairman and CEO, Mike Mahoney, along with Dr. Brad Sutton, chief medical officer of Atrial Fibrillation Solutions, will engage in a 35-minute Q&A session with the host analyst, starting at approximately 8:00 a.m. ET.

Investors and interested parties can access a live webcast of the session through the Boston Scientific investor relations website. A replay of the event will be made available about an hour after its conclusion, providing an opportunity for those unable to attend the live session to catch up on the discussion.

Boston Scientific (NYSE: BSX) has announced the election of David Habiger to its board of directors, effective immediately. Habiger brings over 30 years of business leadership experience and currently serves as president and CEO of J.D. Power. He has previously led several technology companies and is a director on the Chicago Federal Reserve Board. Boston Scientific's CEO, Mike Mahoney, welcomed Habiger, citing his experience in leading technology companies through pivotal growth periods as a valuable asset to the company's board.

Habiger's extensive background includes founding Silicon Media Partners and serving as CEO for companies like Textura, NDS Group, and Sonic Solutions. He holds an M.B.A. from The University of Chicago and a bachelor's degree in business administration from St. Norbert College. His appointment is expected to contribute to Boston Scientific's ongoing efforts to deliver transformative healthcare solutions.

Boston Scientific (NYSE: BSX) reported strong Q2 2024 results, with net sales of $4.120 billion, up 14.5% on a reported basis and 14.7% organically. GAAP EPS was $0.22, while adjusted EPS reached $0.62, exceeding guidance. The company saw significant growth across segments, with Cardiovascular up 17.8% and MedSurg up 9.0%. Regionally, U.S. sales grew 16.9%, and Emerging Markets increased 14.8%. Key developments include NMPA approval in China for the FARAPULSE™ PFA System and positive clinical trial results for various products. Boston Scientific also announced plans to acquire Silk Road Medical. The company raised its full-year 2024 guidance, projecting net sales growth of 13.5-14.5% on a reported basis and adjusted EPS of $2.38-$2.42.

Boston Scientific (NYSE: BSX) announced it will hold a webcast to discuss its Q2 2024 financial results and business highlights on July 24, 2024, at 8:00 a.m. ET.

The call will be led by CEO Mike Mahoney and CFO Dan Brennan, with a news release detailing the financial results to be issued prior to the call. Investors can access the live webcast and a replay at the company's investor relations site starting one hour after the event.

Boston Scientific (NYSE: BSX) has agreed to acquire Silk Road Medical (Nasdaq: SILK) for $27.50 per share, valuing the transaction at approximately $1.16 billion. The acquisition adds Silk Road's FDA-approved TCAR technology for stroke prevention to Boston Scientific's vascular portfolio. TCAR, a minimally invasive procedure, has shown reduced stroke risks and complications compared to traditional surgery. Silk Road Medical expects net revenue of $194-198 million in 2024, marking a 10-12% increase from the previous year. The transaction is set to close in the second half of 2024, with minimal impact on Boston Scientific's adjusted earnings per share in 2024 and 2025, and potential accretive effects thereafter.

Boston Scientific announced positive six-month results from the MODULAR ATP study of the mCRM System, which integrates the EMBLEM S-ICD and EMPOWER LP. The study met all safety and efficacy endpoints, showing a 97.5% major complication-free rate and a 98.8% communication success rate between devices. The ATP success rate was 61.3%, with no patients requesting therapy deactivation. The EMPOWER LP demonstrated stable device fixation. Findings were presented at Heart Rhythm 2024 and published in The New England Journal of Medicine. The APPRAISE ATP trial also supported the modular therapy approach, showing a small reduction in first all-cause shocks over five years in a large patient group. FDA approval is anticipated in 2025.